AstraZeneca easily delivered on chief executive Pascal Soriot’s pledge to deliver $45 billion in revenues by 2023, set a decade earlier as he fended off a takeover bid by
The biotech industry experienced heady highs in early 2021, but has since suffered from a tight financial climate that has brought bankruptcies and widespread redundancies.
With sales of its COVID-19 vaccines on the wane, Moderna has showcased the projects it will look to for the next phase of its development, headed by new vaccines for influ
GSK continued a run of several consecutive quarters of solid growth in the fourth quarter of 2022, helped by shingles vaccine Shingrix, but it needs to build up its pipeli